The board of directors of WuXi Biologics (Cayman) Inc. announced that Mr. William Robert Keller and Mr. Kenneth Walton Hitchner III have been appointed as members of the strategy committee of the Company by the Board with effect from November 23, 2022. Since joining the Group, Mr. Keller and Mr. Hitchner have been providing advice to the Board as independent non-executive directors of the Company. Their wealth of experience in the pharmaceutical industry has been valuable in expanding the Group's capabilities and capacity to provide a comprehensive and integrated CRDMO platform of services for global customers.
Biographical details of Mr. Keller and Mr. Hitchner are set out in the Company's annual report for the year ended December 31, 2021. As at the date of this announcement, the Strategy Committee comprises Dr. Zhisheng Chen (chairman), Dr. Ge Li, Mr. Yibing Wu, Dr. Weichang Zhou, Mr. Keller and Mr. Hitchner.